Voyager Therapeutics names Robin Swartz President; slated to succeed CEO Sandrock after Q1 2027 VY1706 safety data

Voyager Therapeutics, Inc.

Swartz, 56, becomes President effective Oct 20, 2026; she has been COO and Chief Business Officer since Nov 2024 and Principal Financial Officer/Treasurer since May 2026.
CEO transition expected after initial acute safety data from the VY1706 trial in early Alzheimer's, anticipated in Q1 2027; Alfred Sandrock is expected to remain on the Board.
Swartz base salary $625,000 with a 50% target bonus; she receives an option for 318,500 shares and 68,250 RSUs granted Nov 1, 2026 under the 2025 Stock Incentive Plan.
Severance on termination without cause or for good reason: 12 months base salary, pro rata target bonus and up to 12 months COBRA; full equity acceleration if within 12 months after a sale event.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.